.Attribute Medicine, Posted online: thirteen September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized phase 3b/4 DESTINY-Breast12 research study, trastuzumab deruxtecan (T-DXd) treatment of individuals with HER2+ sophisticated breast cancer cells and active or even steady human brain metastases showed constant intracranial task as well as systemic efficacy of T-DXd.